Affiliation:
1. Ryazan State Medical University named after academician I.P. Pavlov; City Clinical Hospital of Emergency Medical Care
Abstract
The aim of the study - to analyze the pathogenesis of liver damage in COVID-19, as well as to study the features of diagnosis. Research materials: literature and own data on the peculiarities of the pathogenesis of liver damage were analyzed, as well as an assessment of laboratory and instrumental diagnostics in patients with COVID-19. The results of the research. In patients, liver damage was manifested by an increase in liver enzymes, as well as a diffuse decrease in its density during CT. The severity of the disease is caused by a cytokine storm caused by a dysfunctional immune response to the virus, viral virulence factors, as well as the presence of concomitant diseases, especially those associated with liver pathology, such as cirrhosis or steatosis. Conclusions. The new COVID-19 coronavirus infection caused by SARS-CoV-2 continues to spread worldwide. The main target is the organs of the respiratory system. However, among the patients with COVID-19, there were lesions of the central nervous system, intestines, myocardium and liver. Liver dysfunction in most cases should be considered as a result of secondary damage due to CVD, ARDS, hypoxia, multiple organ failure, exposure to immune factors, and taking hepatotoxic drugs.
Publisher
LLC Global Media Technology
Reference21 articles.
1. Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020 Jun;83(6):521-523. doi: 10.1097/JCMA.0000000000000319.
2. Zairatiants O.V. Pathological anatomy of COVID-19. Atlas. Moscow., DZM, 2020. 116 p. (in Russ.)@@ Patologicheskaya anatomiya COVID-19. Atlas / Pod obshchei red. Zairat'yantsa O.V. M.: DZM, 2020. 116 c.
3. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARSCoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181 (2): 271-280.e8. doi: 10.1016/j.cell.2020.02.052.
4. Cai Q., Huang D., Yu H. et al. COVID-19: Abnormal liver function tests. J. Hepatol. 2020; S0168-8278(20)30218-X. doi: 10.1016/j.jhep.2020.04.006
5. Zhang C., Shi L., Wang F.S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 2020; 5 (5): 428-430. doi: 10.1016/S2468-1253(20)30057-1.